Screening of novel HSP-inducing compounds to conserve cardiomyocyte function in experimental atrial fibrillation

Denise M. S. van Marion, Xu Hu, Deli Zhang, Femke Hoogstra-Berends, Jean-Paul G. Seerden, Lizette Loen, Andre Heeres, Herman Steen, Robert H. Henning, Bianca J. J. M. Brundel

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background: The heat shock protein (HSP) inducer, geranylgeranylacetone (GGA), was previously found to protect against atrial fibrillation (AF) remodeling in experimental model systems. Clinical application of GGA in AF is limited, due to low systemic concentrations owing to the hydrophobic character of GGA. Objectives: To identify novel HSP-inducing compounds, with improved physicochemical properties, that prevent contractile dysfunction in experimental model systems for AF. Methods: Eighty-one GGA-derivatives were synthesized and explored for their HSP-inducing properties by assessment of HSP expression in HL-1 cardiomyocytes pretreated with or without a mild heat shock (HS), followed by incubation with 10 µM GGA or GGA-derivative. Subsequently, the most potent HSP-inducers were tested for preservation of calcium transient (CaT) amplitudes or heart wall contraction in pretreated tachypaced HL-1 cardiomyocytes (with or without HSPB1 siRNA) and Drosophilas, respectively. Finally, CaT recovery in tachypaced HL-1 cardiomyocytes posttreated with GGA or protective GGA-derivatives was determined. Results: Thirty GGA-derivatives significantly induced HSPA1A expression after HS, and seven showed exceeding HSPA1A expression compared to GGA. GGA and nine GGA-derivatives protected significantly from tachypacing (TP)-induced CaT loss, which was abrogated by HSPB1 suppression. GGA and four potent GGA-derivatives protected against heart wall dysfunction after TP compared to non-paced control Drosophilas. Of these compounds, GGA and three GGA-derivatives induced a significant restoration from CaT loss after TP of HL-1 cardiomyocytes. Conclusion: We identified novel GGA-derivatives with improved physicochemical properties compared to GGA. GGA-derivatives, particularly GGA*-59, boost HSP expression resulting in prevention and restoration from TP-induced remodeling, substantiating their role as novel therapeutics in clinical AF.

Original languageEnglish
Pages (from-to)345-364
JournalDRUG DESIGN DEVELOPMENT AND THERAPY
Volume13
DOIs
Publication statusPublished - 1 Jan 2019

Cite this

van Marion, Denise M. S. ; Hu, Xu ; Zhang, Deli ; Hoogstra-Berends, Femke ; Seerden, Jean-Paul G. ; Loen, Lizette ; Heeres, Andre ; Steen, Herman ; Henning, Robert H. ; Brundel, Bianca J. J. M. / Screening of novel HSP-inducing compounds to conserve cardiomyocyte function in experimental atrial fibrillation. In: DRUG DESIGN DEVELOPMENT AND THERAPY. 2019 ; Vol. 13. pp. 345-364.
@article{b9f1f26b692a4855b35c0fdf1bba6f94,
title = "Screening of novel HSP-inducing compounds to conserve cardiomyocyte function in experimental atrial fibrillation",
abstract = "Background: The heat shock protein (HSP) inducer, geranylgeranylacetone (GGA), was previously found to protect against atrial fibrillation (AF) remodeling in experimental model systems. Clinical application of GGA in AF is limited, due to low systemic concentrations owing to the hydrophobic character of GGA. Objectives: To identify novel HSP-inducing compounds, with improved physicochemical properties, that prevent contractile dysfunction in experimental model systems for AF. Methods: Eighty-one GGA-derivatives were synthesized and explored for their HSP-inducing properties by assessment of HSP expression in HL-1 cardiomyocytes pretreated with or without a mild heat shock (HS), followed by incubation with 10 µM GGA or GGA-derivative. Subsequently, the most potent HSP-inducers were tested for preservation of calcium transient (CaT) amplitudes or heart wall contraction in pretreated tachypaced HL-1 cardiomyocytes (with or without HSPB1 siRNA) and Drosophilas, respectively. Finally, CaT recovery in tachypaced HL-1 cardiomyocytes posttreated with GGA or protective GGA-derivatives was determined. Results: Thirty GGA-derivatives significantly induced HSPA1A expression after HS, and seven showed exceeding HSPA1A expression compared to GGA. GGA and nine GGA-derivatives protected significantly from tachypacing (TP)-induced CaT loss, which was abrogated by HSPB1 suppression. GGA and four potent GGA-derivatives protected against heart wall dysfunction after TP compared to non-paced control Drosophilas. Of these compounds, GGA and three GGA-derivatives induced a significant restoration from CaT loss after TP of HL-1 cardiomyocytes. Conclusion: We identified novel GGA-derivatives with improved physicochemical properties compared to GGA. GGA-derivatives, particularly GGA*-59, boost HSP expression resulting in prevention and restoration from TP-induced remodeling, substantiating their role as novel therapeutics in clinical AF.",
keywords = "Drosophila, atrial fibrillation, geranylgeranylacetone, heat shock protein, proteostasis",
author = "{van Marion}, {Denise M. S.} and Xu Hu and Deli Zhang and Femke Hoogstra-Berends and Seerden, {Jean-Paul G.} and Lizette Loen and Andre Heeres and Herman Steen and Henning, {Robert H.} and Brundel, {Bianca J. J. M.}",
year = "2019",
month = "1",
day = "1",
doi = "10.2147/DDDT.S176924",
language = "English",
volume = "13",
pages = "345--364",
journal = "DRUG DESIGN DEVELOPMENT AND THERAPY",
issn = "1177-8881",
publisher = "Dove Medical Press Ltd.",

}

Screening of novel HSP-inducing compounds to conserve cardiomyocyte function in experimental atrial fibrillation. / van Marion, Denise M. S.; Hu, Xu; Zhang, Deli; Hoogstra-Berends, Femke; Seerden, Jean-Paul G.; Loen, Lizette; Heeres, Andre; Steen, Herman; Henning, Robert H.; Brundel, Bianca J. J. M.

In: DRUG DESIGN DEVELOPMENT AND THERAPY, Vol. 13, 01.01.2019, p. 345-364.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Screening of novel HSP-inducing compounds to conserve cardiomyocyte function in experimental atrial fibrillation

AU - van Marion, Denise M. S.

AU - Hu, Xu

AU - Zhang, Deli

AU - Hoogstra-Berends, Femke

AU - Seerden, Jean-Paul G.

AU - Loen, Lizette

AU - Heeres, Andre

AU - Steen, Herman

AU - Henning, Robert H.

AU - Brundel, Bianca J. J. M.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: The heat shock protein (HSP) inducer, geranylgeranylacetone (GGA), was previously found to protect against atrial fibrillation (AF) remodeling in experimental model systems. Clinical application of GGA in AF is limited, due to low systemic concentrations owing to the hydrophobic character of GGA. Objectives: To identify novel HSP-inducing compounds, with improved physicochemical properties, that prevent contractile dysfunction in experimental model systems for AF. Methods: Eighty-one GGA-derivatives were synthesized and explored for their HSP-inducing properties by assessment of HSP expression in HL-1 cardiomyocytes pretreated with or without a mild heat shock (HS), followed by incubation with 10 µM GGA or GGA-derivative. Subsequently, the most potent HSP-inducers were tested for preservation of calcium transient (CaT) amplitudes or heart wall contraction in pretreated tachypaced HL-1 cardiomyocytes (with or without HSPB1 siRNA) and Drosophilas, respectively. Finally, CaT recovery in tachypaced HL-1 cardiomyocytes posttreated with GGA or protective GGA-derivatives was determined. Results: Thirty GGA-derivatives significantly induced HSPA1A expression after HS, and seven showed exceeding HSPA1A expression compared to GGA. GGA and nine GGA-derivatives protected significantly from tachypacing (TP)-induced CaT loss, which was abrogated by HSPB1 suppression. GGA and four potent GGA-derivatives protected against heart wall dysfunction after TP compared to non-paced control Drosophilas. Of these compounds, GGA and three GGA-derivatives induced a significant restoration from CaT loss after TP of HL-1 cardiomyocytes. Conclusion: We identified novel GGA-derivatives with improved physicochemical properties compared to GGA. GGA-derivatives, particularly GGA*-59, boost HSP expression resulting in prevention and restoration from TP-induced remodeling, substantiating their role as novel therapeutics in clinical AF.

AB - Background: The heat shock protein (HSP) inducer, geranylgeranylacetone (GGA), was previously found to protect against atrial fibrillation (AF) remodeling in experimental model systems. Clinical application of GGA in AF is limited, due to low systemic concentrations owing to the hydrophobic character of GGA. Objectives: To identify novel HSP-inducing compounds, with improved physicochemical properties, that prevent contractile dysfunction in experimental model systems for AF. Methods: Eighty-one GGA-derivatives were synthesized and explored for their HSP-inducing properties by assessment of HSP expression in HL-1 cardiomyocytes pretreated with or without a mild heat shock (HS), followed by incubation with 10 µM GGA or GGA-derivative. Subsequently, the most potent HSP-inducers were tested for preservation of calcium transient (CaT) amplitudes or heart wall contraction in pretreated tachypaced HL-1 cardiomyocytes (with or without HSPB1 siRNA) and Drosophilas, respectively. Finally, CaT recovery in tachypaced HL-1 cardiomyocytes posttreated with GGA or protective GGA-derivatives was determined. Results: Thirty GGA-derivatives significantly induced HSPA1A expression after HS, and seven showed exceeding HSPA1A expression compared to GGA. GGA and nine GGA-derivatives protected significantly from tachypacing (TP)-induced CaT loss, which was abrogated by HSPB1 suppression. GGA and four potent GGA-derivatives protected against heart wall dysfunction after TP compared to non-paced control Drosophilas. Of these compounds, GGA and three GGA-derivatives induced a significant restoration from CaT loss after TP of HL-1 cardiomyocytes. Conclusion: We identified novel GGA-derivatives with improved physicochemical properties compared to GGA. GGA-derivatives, particularly GGA*-59, boost HSP expression resulting in prevention and restoration from TP-induced remodeling, substantiating their role as novel therapeutics in clinical AF.

KW - Drosophila

KW - atrial fibrillation

KW - geranylgeranylacetone

KW - heat shock protein

KW - proteostasis

UR - http://www.scopus.com/inward/record.url?scp=85060946510&partnerID=8YFLogxK

U2 - 10.2147/DDDT.S176924

DO - 10.2147/DDDT.S176924

M3 - Article

VL - 13

SP - 345

EP - 364

JO - DRUG DESIGN DEVELOPMENT AND THERAPY

JF - DRUG DESIGN DEVELOPMENT AND THERAPY

SN - 1177-8881

ER -